Summarized by Masters of Longevity from Peter Attia Blog.
This piece previews a science-focused article examining whether a late-life diabetes drug could influence aging in mice, inviting curiosity about study design and implications.
Key Takeaways
- Female mice started on clinically scaled semaglutide late in life showed a median lifespan of 834 days versus 742 days for controls.
- Semaglutide-treated mice ate about 24% less, lost primarily fat mass, and had proportionally larger gastrocnemius muscle.
- Control cohort lifespan was shorter than many historical reports, so findings require replication in independent cohorts and sexes.
